The global blood transfusion diagnostics market was valued at US$2.451 billion in 2020 and is expected to grow at a CAGR of 6.28% over the forecast period to reach a total market size of US$3.755 billion by 2027.
Blood transfusion diagnostics refers to testing conducted on blood and blood components prior to transfusion to patients. To avoid adverse reactions or infection transmission, each blood unit must be checked for blood group type and disease screening. It is an essential component of transfusion treatment since it offers vital information to healthcare practitioners and validates the compatibility of donor and recipient blood samples. Red blood cells are the most frequently transfused blood products. Molecular blood group diagnosis is one of the transfusion diagnostics. For patients who have antibodies against clinically relevant, uncommon, or weak antigens, molecular blood group diagnosis allows for safer blood storage and on-demand supplies.
Developing and underdeveloped countries lack proper blood banks, medical equipment required for blood transfusion, adequate conditions for blood storage, and a limited supply of blood in response to high demand. Hospitals lack the necessary amenities to deliver hygienic and safe transfusions. Thus, the escalating burden of chronic disorders and the rising need for donor screening are boosting the market’s growth. Furthermore, the rising need for transfusions because of trauma, car accidents, and surgical procedures is favourably influencing the market.
The emergence of advanced molecular platforms by market leaders accelerates the transition from manual testing and equipment to semi-automated and fully automated devices. These automated systems have been critical in detecting transfusion transmissible infections (TTIs) in blood samples and can accurately remove human error throughout the transfusion procedure.
During the forecast period, North America is expected to be the largest regional market for the global blood transfusion diagnostics market. This dominance can be attributed to increased acceptance of the blood transfusion procedure, increased public awareness regarding blood donations, and developed healthcare infrastructure. According to data released by the National Center for Biotechnology Information, over 15 million blood units are transfused in the United States each year, with an estimated 85 million units transfused globally.
The rising prevalence of blood-related conditions such as haemophilia, cancer, thrombocytopenia, and others, as well as chronic kidney disease (CKD), has increased the demand for blood transfusions. According to World Kidney Day estimates, about 850 million individuals worldwide will be suffering from kidney diseases in 2020. In addition, one out of every ten individuals has chronic kidney disease (CKD), which is predicted to become the sixth leading cause of death by the end of 2040. Furthermore, the growing number of patients suffering from anaemia necessitates red blood cell transfusion for treatment, which is further driving up the demand for blood transfusion diagnostics. The World Health Organization (WHO) estimates that anaemia affects around 1.62 billion people worldwide. This, together with increased awareness regarding blood safety from infectious diseases through various initiatives in developed and developing nations, is driving up demand for blood screening tests and other diagnostic instruments.
Despite the rising prevalence of chronic blood disorders and increased demand for blood transfusions, several issues are impeding the market’s growth. One of the causes is a lack of investment in healthcare infrastructure and strict government policies, particularly in developing nations when compared to developed countries. Furthermore, the high cost of tests, instruments, and reagents, along with a shortage of qualified professionals to handle automated diagnostic solutions, is one of the factors restraining the growth of the blood transfusion diagnostics market during the forecast period.
The Impact of COVID-19 on the Blood Transfusion Diagnostics Market:
The COVID-19 pandemic had a detrimental impact on the market. The outbreak reduced the number of voluntary blood donors and affected the global supply chain of medical equipment. Some of the primary problems encountered by blood banks and hospitals during the crisis included decreased donor inflow, a lack of staff personnel, a scarcity of blood units, and public anxiety over transfusion-transmitted COVID-19. According to the American Red Cross, the organisation lost around 46,000 blood unit donations due to the pandemic. In addition, a few donor locations saw a significant decrease in blood donations due to lockdowns and suspension of blood drives. However, by the third quarter of 2020, most countries had lifted lockdown and stay-at-home rules, resulting in an increase in blood donations and transfusion operations across all blood centres.
Officials from the State Blood Transfusion Council (SBTC) reported in September 2021 that supplies in Maharashtra blood banks would barely last a week. This drop was attributed to a decrease in blood donation camps, reduced donor footfall owing to the pandemic, and the closure of offices and institutions in the state.
The American Red Cross started a new nationwide initiative in September 2021 to reach out to more black blood donors in order to aid patients with sickle cell disease and improve health outcomes. Blood donations from individuals of the same race or ethnicity as well as blood type are the most reliable option to treat sickle cell patients.
|Market size value in 2020||US$2.451 billion|
|Market size value in 2027||US$3.755 billion|
|Growth Rate||CAGR of 6.28% from 2020 to 2027|
|Forecast Unit (Value)||USD Billion|
|Segments covered||Type, Technology, End-User, And Geography|
|Regions covered||North America, South America, Europe, Middle East and Africa, Asia Pacific|
|Companies covered||Quotient Ltd., BAG Healthcare, Abbott, Immucor, Diasorin SPA, Bio-Rad Laboratories Inc., Grifols S.A., F. Hoffmann La Roche Ltd., Beckman Coulter Inc., DIAGAST|
|Customization scope||Free report customization with purchase|
Frequently Asked Questions (FAQs)
Q1. What are the growth prospects for the blood transfusion diagnostics market?
A1. The blood transfusion diagnostics market is expected to grow at a CAGR of 6.28% during the forecast period.
Q2. What will be the blood transfusion diagnostics market size by 2027?
A2. The global blood transfusion diagnostics market is expected to reach a market size of US$3.755 billion by 2027.
Q3. What is the size of the global blood transfusion diagnostics market?
A3. Blood Transfusion Diagnostics Market was valued at US$2.451 billion in 2020.
Q4. Which region holds the maximum market share in the blood transfusion diagnostics market?
A4. North America is expected to hold a largest share for the global blood transfusion diagnostics market owing to to increased acceptance of the blood transfusion procedure, increased public awareness regarding blood donations, and developed healthcare infrastructure.
Q5. What factors are anticipated to drive the blood transfusion diagnostics market growth?
A5. The escalating burden of chronic disorders and the rising need for donor screening are boosting the blood transfusion diagnostics market growth.
Bio-Rad Laboratories Inc.
F. Hoffmann La Roche Ltd.
Beckman Coulter Inc.
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.